Gemcitabine
Gemcitabine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Intrahepatic Cholangiocarcinoma、Breast Neoplasms、Hodgkin Lymphoma、Relapsed or Refractory Hodgkin Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
4 项
已进入 III/IV 期
13 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Francesco De Cobelli
- BioNTech SE
- Memorial Sloan Kettering Cancer Center
- Revolution Medicines, Inc.
- Phanes Therapeutics
- Kochi University
- UNC Lineberger Comprehensive Cancer Center
- Sun Yat-sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
日本、美国、中国、比利时、法国、英国、中国台湾、Israel、澳大利亚、加拿大、德国、意大利
正在招募患者的 Gemcitabine 研究
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
II 期 / III 期招募中日本NCT05268692Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Safety and Efficacy of Pucotenlimab in pLECC
II 期招募中中国NCT06969534Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
不适用招募中中国NCT05595408Histotripsy in Biliary Tract Cancer
不适用招募中美国NCT07853690DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
I 期 / II 期招募中中国NCT07059650The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
IV 期招募中中国NCT06368063Personalized Medicine for Advanced Biliary Cancer Patients
III 期招募中比利时法国英国NCT05615818Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
不适用招募中中国NCT05892354Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
不适用招募中中国NCT06889623Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma
I 期招募中中国台湾NCT06229496Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
II 期招募中中国NCT06721286AB122 Platform Study
I 期招募中日本NCT04999761A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
II 期招募中美国Israel日本中国台湾NCT07769502Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
II 期招募中法国NCT03364530A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
I 期招募中中国NCT06181032Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
II 期招募中美国澳大利亚加拿大法国NCT06806033Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
II 期招募中中国NCT07267078EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
I 期 / II 期招募中中国NCT06802835GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
II 期招募中中国NCT05557578Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
II 期招募中美国NCT07201519GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
II 期招募中中国NCT06455410Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
I 期 / II 期招募中中国NCT06829771TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
III 期招募中中国NCT07047365
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。